Medigen Biotechnology Corporation operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Medigen Biotechnology with three other
companies in this sector in Taiwan:
Welgene Biotech Co Ltd
sales of 384.43 million Taiwanese Dollars [US$12.60 million]
Genomics Biosci &Tech Co Ltd
(438.69 million Taiwanese Dollars [US$14.38 million]
Sofiva Genomics Co Ltd
(459.40 million Taiwanese Dollars [US$15.05 million]
of which 96%
was Testing service-Taiwan).
Medigen Biotechnology reported sales of 407.31 million Taiwanese Dollars (US$13.35 million)
December of 2018.
decrease of 11.0%
versus 2017, when the company's sales were 457.78 million Taiwanese Dollars.
Contributing to the drop in overall sales was the 5.4% decline
in Drug Discovery, from 356.78 million Taiwanese Dollars to 337.48 million Taiwanese Dollars.
However, these declines were partially offset by the increase in sales of
Nucleic Acid Test (up 6.7% to 107.72 million Taiwanese Dollars)